



The Heart of Industry

## Results of Operations for the First Quarter of the Fiscal Year Ending March 31, 2024 (FY3/24)

August 10, 2023

**IWAKI CO.,LTD.**

Stock code: 6237  
Trade name: Iwaki Pump



Chemical feeding unit ETU series (ETU-25)  
A combination of an electromagnetic metering pump and a  
chemical tank achieves an optimal structure for feeding chemicals

# Financial Summary



Sales were firm in all market categories. Strong sales in the semiconductor/liquid crystal, medical equipment and water treatment categories were the primary source of growth.

As with sales, profits are poised to surge as well. This boost is attributed to the consolidation of two subsidiaries, Iwaki Hong Kong Group and Iwaki Shanghai, in the fourth quarter of the previous fiscal year. Additionally, the increased sales from our other subsidiaries had a positive impact on our overall profitability.

		1Q FY3/23	1Q FY3/24*		
		Amount (Millions of yen)	Amount (Millions of yen)	Differences	YoY change
Net sales		8,390	<b>11,107</b>	2,717	+32.4%
Gross profit (Gross margin)		2,956 (35.2%)	<b>4,271</b> <b>(38.5%)</b>	1,314	+44.5%
Operating profit (Operating margin)		744 (8.9%)	<b>1,451</b> <b>(13.1%)</b>	707	+94.9%
Ordinary profit		1,158	<b>1,782</b>	624	+53.9%
Profit attributable to owners of parent		974	<b>1,222</b>	248	+25.5%
Net income per share (Yen)		44.47	<b>55.65</b>	11.19	+25.2%
Exchange rate (average)	USD/JPY (Yen)	116.34	132.40		
	EUR/JPY (Yen)	130.40	142.13		
	HKD/JPY (Yen)	-	16.89		
	CNY/JPY (Yen)	-	19.34		

\* Because the allocation of the acquisition cost for Iwaki Hong Kong Group and Iwaki Shanghai has not been completed at this time, the amortization of goodwill in the first quarter of FY3/24 is carried out using provisional accounting treatment.

**1**

## **Sales: Up 32.4% – Achieved robust YoY growth on a consolidated basis across all markets and products, with double-digit increase in each segment**

- Sales witnessed substantial growth across all markets, driven in part by the positive contributions from recently consolidated subsidiaries (Iwaki Hong Kong Group and Iwaki Shanghai.)
- The newly consolidated subsidiaries in 1Q FY3/24 added sales of ¥1,705 million (before consolidation adjustments).
- Iwaki Hong Kong Group primarily thrives in the medical equipment market, whereas Iwaki Shanghai's strength lies in the semiconductor/liquid crystal markets.
- The U.S. water treatment market also remained strong.
- Conversely, sales in the Asian region, particularly Taiwan, faced challenges due to the downturn in the semiconductor market.

**2**

## **Operating profit: Up 94.9% partially due to positive impacts from newly consolidated subsidiaries and sales growth from other sources**

- The newly consolidated subsidiaries in 1Q FY3/24 added ¥588 million to operating profit (before consolidation adjustments).
- While price hikes did not fully offset the substantial cost increases, the rise in sales resulted in an increase in profit, excluding the impact of newly consolidated subsidiaries.

**3**

## **Profit attributable to owners of parent: Up 25.5% compared to the same period a year earlier**

- Despite several factors that contributed to lower profits, including the absence of Iwaki Hong Kong Group and Iwaki Shanghai, and a decrease in equity in earnings of Iwaki Taiwan, along with increased interest expenses, profit increased by a double-digit figure.

## FY3/24 Forecast



Forecast double-digit sales growth due to the first full-year contribution of newly consolidated subsidiaries and other reasons.

Forecast higher earnings but a decrease in profit attributable to owners of parent because of the large extraordinary income in FY3/23.


	FY3/23*		FY3/24 (Forecast)	
	Amount (Millions of yen)	Amount (Millions of yen)	Differences	YoY change
Net sales	37,730	<b>44,181</b>	6,450	+17.1%
Gross profit (Gross margin)	12,923 (34.3%)	<b>16,600</b> <b>(37.6%)</b>	3,676	+28.4%
Operating profit (Operating margin)	2,443 (6.5%)	<b>3,920</b> <b>(8.9%)</b>	1,477	+60.5%
Ordinary profit	3,933	<b>4,302</b>	368	+9.4%
Profit attributable to owners of parent	4,398	<b>3,115</b>	-1,283	-29.2%
Net income per share (Yen)	200.35	<b>141.79</b>	-58.56	-29.2%
Return on equity (ROE)	16.3%	<b>10.4%</b>	-	(-5.8pt)
Return on invested capital (ROIC)	7.4%	<b>9.3%</b>	-	(+1.9pt)
Exchange rate (average)	USD/JPY (Yen)	131.64	136.00	
	EUR/JPY (Yen)	138.15	143.00	
	HKD/JPY (Yen)	18.08	17.40	
	CNY/JPY (Yen)	19.86	19.70	

\* Because the allocation of the acquisition cost for Iwaki Hong Kong Group and Iwaki Shanghai has not been completed at this time, the amortization of goodwill in FY3/23 was carried out using provisional accounting treatment.

# Net Sales and Operating Profit (Quarterly)



Sales were higher than in the previous quarter mainly due to sales growth in the U.S., Hong Kong and Shanghai. First quarter operating profit and ordinary profit were much higher than in the previous quarter. This was mainly attributable to higher sales and to expenses for bonuses for executives linked to results of operations and the increase in bonuses paid to employees in the previous quarter.




# Gross Margin and SG&A Expense Ratio (Quarterly)









In the previous quarter, there was an increase in bonuses linked to results of operations for executives and employee bonuses.

The elevated SG&A expenses in the first quarter were primarily attributed to the consolidation of Iwaki Hong Kong Group and Iwaki Shanghai.



# Market Overview for Product Categories

Sold in many markets	Major pump applications	Magnetic drive pumps 	Metering pumps 	Pneumatic drive pumps 	Rotary displacement pumps 	Air pumps 	Systems products 
<b>Semiconductor/liquid crystal</b>	Semiconductor production equipment, etc.	●	○	●			○
<b>Medical equipment</b>	Dialysis equipment and clinical trial equipment, etc.	○	○		●	●	○
<b>Surface treatment equipment</b>	Printed circuit board manufacturing equipment, electronic component manufacturing, etc.	●	○				○
<b>Chemicals</b>	Liquid chemical manufacturing, etc.	●	○		○		○
<b>Water treatment</b>	Water purification plant, wastewater treatment, cooling towers, etc.	○	●		○	○	○
<b>New energy</b>	Renewable energy, rechargeable battery production, etc.	○	○		●		○
<b>Others (Food, paper, others)</b>	Food cleansing, cooling applications, etc.	○	○		●	○	○

\* A filled circle means major pumps in each market.


# Profitability of Products

Profitability

High



Low




\*Excluding systems products, purchased products and other



# Market Category Sales



Water treatment sales remain strong, chiefly in the U.S. Strong performance in the semiconductor/liquid crystal category is mainly attributed to the inclusion of Iwaki Shanghai in consolidation. Even excluding this impact, sales were higher mainly in Japan and the U.S. In the medical equipment market, the consolidation of Iwaki Hong Kong Group had a noteworthy impact on sales. Increase in sales in Japan also contributed to sales.




# Product Category Sales



Our core products, magnetic drive pumps, and metering pumps, both experienced double-digit growth, which in turn propelled our overall sales.

Despite an overall slowdown in the semiconductor market, sales of pneumatic pumps, primarily for the semiconductor/liquid crystal category, experienced an uptick. This increase is attributed to the backlog of orders and the impact of including Iwaki Shanghai in the consolidation.




	1Q FY3/24 sales (Millions of yen)	YoY change (Millions of yen)	YoY change (%)
Magnetic drive pumps	3,522	921	+35.4%
Metering pumps	1,849	395	+27.2%
Pneumatic drive pumps	1,607	284	+21.5%
Rotary displacement pumps	661	200	+43.5%
Air pumps	644	193	+42.7%
Systems products	433	84	+24.4%
Purchased products	694	98	+16.5%
Others	1,693	538	+46.6%

# Regional Sales



Sales to Taiwan, which represent the majority of sales in the semiconductor/liquid crystal and surface treatment equipment markets, were sluggish, and sales to Asia were weak. On the other hand, sales to China saw a significant increase, primarily due to the consolidation of new subsidiaries.





## The Heart of Industry

We will continue to support industries at the forefront to contribute to the development of society and the happiness of people

For more information:  
Corporate Planning Section,  
Business Management Department,  
Business Management Head Office,  
IWAKI CO.,LTD.

E-mail: [ir@iwakipumps.jp](mailto:ir@iwakipumps.jp)

Operating hours: 9:00 to 17:30

(Except Saturdays, Sundays, public holidays, and other business holidays)

- This presentation was prepared by IWAKI to provide information to investors about business operations.
- Information in this presentation is based on reasonable judgments by IWAKI using generally accepted views of economic, social and other factors as of August 10, 2023. This information may have to be revised without prior notice in the event of a change in the business climate or some other event.
- The information in this presentation includes forward-looking statements. These statements are current outlooks, forecasts and assumptions that include risk and incorporate uncertainties that may cause actual performance to differ from these statements.
- Risk factors and other uncertainties include but are not limited to items related to the Japanese and global economies, such as changes in business and market conditions and in interest rates and exchange rates.
- IWAKI has no obligation to update or revise the forward-looking statements in this presentation even if there is new information, a significant event or some other reason for a change.
- This document has been translated from the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail.
- IWAKI assumes no responsibility for this translation or for direct, indirect or any other forms of damages arising from the translation.